Jong Y Park

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/5451183/publications.pdf

Version: 2024-02-01

120 papers	6,404 citations	39 h-index	7	74 g-index
130 all docs	130 docs citations	130 times ranked		10376 citing authors

#	Article	IF	Citations
1	Performance of African-ancestry-specific polygenic hazard score varies according to local ancestry in 8q24. Prostate Cancer and Prostatic Diseases, 2022, 25, 229-237.	3.9	9
2	Prostate cancer risk stratification improvement across multiple ancestries with new polygenic hazard score. Prostate Cancer and Prostatic Diseases, 2022, 25, 755-761.	3.9	14
3	Substantial Gleason reclassification in Black men with national comprehensive cancer network low-risk prostate cancer – A propensity score analysis. Prostate Cancer and Prostatic Diseases, 2022, 25, 547-552.	3.9	3
4	Dysregulation of DNA Methylation and Epigenetic Clocks in Prostate Cancer among Puerto Rican Men. Biomolecules, 2022, 12, 2.	4.0	1
5	Intake Patterns of Specific Alcoholic Beverages by Prostate Cancer Status. Cancers, 2022, 14, 1981.	3.7	O
6	Translational Genomic Research: The Association between Genetic Profiles and Cognitive Functioning or Cardiac Function Among Breast Cancer Survivors Completing Chemotherapy. Biological Research for Nursing, 2022, , 109980042210943.	1.9	2
7	Anticancer function of <scp>microRNA</scp> â€30e is mediated by negative regulation of <scp><i>HELLPAR</i></scp> , a noncoding <scp>macroRNA</scp> , and genes involved in ubiquitination and cell cycle progression in prostate cancer. Molecular Oncology, 2022, 16, 2936-2958.	4.6	4
8	Reduced DNA Repair Capacity in Prostate Cancer Patients: A Phenotypic Approach Using the CometChip. Cancers, 2022, 14, 3117.	3.7	2
9	Comparative Genomics Reveals Distinct Immune-oncologic Pathways in African American Men with Prostate Cancer. Clinical Cancer Research, 2021, 27, 320-329.	7.0	46
10	TMPRSS2â€ERG fusion impacts anterior tumor location in men with prostate cancer. Prostate, 2021, 81, 109-117.	2.3	4
11	Africanâ€specific improvement of a polygenic hazard score for age at diagnosis of prostate cancer. International Journal of Cancer, 2021, 148, 99-105.	5.1	24
12	Trans-ancestry genome-wide association meta-analysis of prostate cancer identifies new susceptibility loci and informs genetic risk prediction. Nature Genetics, 2021, 53, 65-75.	21.4	264
13	Additional SNPs improve risk stratification of a polygenic hazard score for prostate cancer. Prostate Cancer and Prostatic Diseases, 2021, 24, 532-541.	3.9	16
14	Polygenic hazard score is associated with prostate cancer in multi-ethnic populations. Nature Communications, 2021, 12, 1236.	12.8	40
15	Alcohol Intake and Alcohol–SNP Interactions Associated with Prostate Cancer Aggressiveness. Journal of Clinical Medicine, 2021, 10, 553.	2.4	3
16	KLK3 SNP–SNP interactions for prediction of prostate cancer aggressiveness. Scientific Reports, 2021, 11, 9264.	3.3	5
17	A polymorphism in the promoter of FRAS1 is a candidate SNP associated with metastatic prostate cancer. Prostate, 2021, 81, 683-693.	2.3	5
18	Mindfulness-based stress reduction for breast cancer survivors (MBSR(BC)): evaluating mediators of psychological and physical outcomes in a large randomized controlled trial. Journal of Behavioral Medicine, 2021, 44, 591-604.	2.1	12

#	Article	IF	CITATIONS
19	Marital status and prostate cancer incidence: a pooled analysis of 12 case–control studies from the PRACTICAL consortium. European Journal of Epidemiology, 2021, 36, 913-925.	5.7	23
20	Geospatial Cellular Distribution of Cancer-Associated Fibroblasts Significantly Impacts Clinical Outcomes in Metastatic Clear Cell Renal Cell Carcinoma. Cancers, 2021, 13, 3743.	3.7	13
21	Novel strategy for disease risk prediction incorporating predicted gene expression and DNA methylation data: a multiâ€phased study of prostate cancer. Cancer Communications, 2021, 41, 1387-1397.	9.2	6
22	SNPxE: SNP-environment interaction pattern identifier. BMC Bioinformatics, 2021, 22, 425.	2.6	2
23	Differential DNA Methylation in Prostate Tumors from Puerto Rican Men. International Journal of Molecular Sciences, 2021, 22, 733.	4.1	4
24	Commercial Gene Expression Tests for Prostate Cancer Prognosis Provide Paradoxical Estimates of Race-Specific Risk. Cancer Epidemiology Biomarkers and Prevention, 2020, 29, 246-253.	2.5	19
25	Influence of gene expression on survival of clear cell renal cell carcinoma. Cancer Medicine, 2020, 9, 8662-8675.	2.8	16
26	An integrative multi-omics analysis to identify candidate DNA methylation biomarkers related to prostate cancer risk. Nature Communications, 2020, 11, 3905.	12.8	28
27	Exploring Prostate Cancer Patients' Interest and Preferences for Receiving Genetic Risk Information About Cancer Aggressiveness. American Journal of Men's Health, 2020, 14, 155798832091962.	1.6	3
28	The CHEK2 Variant C.349A>G Is Associated with Prostate Cancer Risk and Carriers Share a Common Ancestor. Cancers, 2020, 12, 3254.	3.7	16
29	A Germline Variant at 8q24 Contributes to Familial Clustering of Prostate Cancer in Men of African Ancestry. European Urology, 2020, 78, 316-320.	1.9	32
30	The effect of sample size on polygenic hazard models for prostate cancer. European Journal of Human Genetics, 2020, 28, 1467-1475.	2.8	14
31	Multifaceted Function of MicroRNA-299-3p Fosters an Antitumor Environment Through Modulation of Androgen Receptor and VEGFA Signaling Pathways in Prostate Cancer. Scientific Reports, 2020, 10, 5167.	3.3	17
32	A Genetic Risk Score to Personalize Prostate Cancer Screening, Applied to Population Data. Cancer Epidemiology Biomarkers and Prevention, 2020, 29, 1731-1738.	2.5	27
33	TGF- \hat{l}^2 induced EMT and stemness characteristics are associated with epigenetic regulation in lung cancer. Scientific Reports, 2020, 10, 10597.	3.3	93
34	Translational genomic research: the role of genetic polymorphisms in MBSR program among breast cancer survivors (MBSR[BC]). Translational Behavioral Medicine, 2019, 9, 693-702.	2.4	8
35	Comparison of PANAMutyper and PNAClamp for Detecting KRAS Mutations from Patients With Malignant Pleural Effusion. In Vivo, 2019, 33, 945-954.	1.3	1
36	Interactions of <i>PVT1</i> and <i>CASC11</i> on Prostate Cancer Risk in African Americans. Cancer Epidemiology Biomarkers and Prevention, 2019, 28, 1067-1075.	2.5	14

#	Article	IF	Citations
37	Hypoxia-induced cancer stemness acquisition is associated with CXCR4 activation by its aberrant promoter demethylation. BMC Cancer, 2019, 19, 148.	2.6	27
38	Comparison of PNA Clamping-assisted Fluorescence Melting Curve Analysis and PNA Clamping in Detecting <i>EGFR</i> Mutations in Matched Tumor Tissue, Cell Block, Pleural Effusion and Blood of Lung Cancer Patients With Malignant Pleural Effusion. In Vivo, 2019, 33, 595-603.	1.3	5
39	Optimizing Time to Treatment to Achieve Durable Biochemical Disease Control after Surgery in Prostate Cancer: A Multi-Institutional Cohort Study. Cancer Epidemiology Biomarkers and Prevention, 2019, 28, 570-577.	2.5	9
40	Circulating Metabolic Biomarkers of Screen-Detected Prostate Cancer in the ProtecT Study. Cancer Epidemiology Biomarkers and Prevention, 2019, 28, 208-216.	2.5	21
41	A test of dopamine hyper- and hyposensitivity in alcohol use. Addictive Behaviors, 2019, 90, 395-401.	3.0	11
42	Aptamer Selection for Detecting Molecular Target Using Cell-SELEX (Systematic Evolution of Ligands) Tj ETQq0 (O OggBT /C	Overlock 10 T
43	African American Specific Gene Panel Predictive of Poor Prostate Cancer Outcome. Journal of Urology, 2019, 202, 247-255.	0.4	19
44	Telomere length in peripheral blood leukocytes and risk of renal cell carcinoma. Translational Cancer Research, 2019, 8, S397-S403.	1.0	2
45	Chronic nicotine exposure affects programmed death-ligand 1 expression and sensitivity to epidermal growth factor receptor-tyrosine kinase inhibitor in lung cancer. Translational Cancer Research, 2019, 8, S378-S388.	1.0	3
46	Micro-RNA-186-5p inhibition attenuates proliferation, anchorage independent growth and invasion in metastatic prostate cancer cells. BMC Cancer, 2018, 18, 421.	2.6	47
47	Polygenic hazard score to guide screening for aggressive prostate cancer: development and validation in large scale cohorts. BMJ: British Medical Journal, 2018, 360, j5757.	2.3	153
48	Africanâ€American men and prostate cancerâ€specific mortality: a competing risk analysis of a large institutional cohort, 1989‰2015. Cancer Medicine, 2018, 7, 2160-2171.	2.8	29
49	Germline variation at 8q24 and prostate cancer risk in men of European ancestry. Nature Communications, 2018, 9, 4616.	12.8	43
50	Tristetraprolin Is a Prognostic Biomarker for Poor Outcomes among Patients with Low-Grade Prostate Cancer. Cancer Epidemiology Biomarkers and Prevention, 2018, 27, 1376-1383.	2.5	9
51	AA9int: SNP interaction pattern search using non-hierarchical additive model set. Bioinformatics, 2018, 34, 4141-4150.	4.1	3
52	Association analyses of more than 140,000 men identify 63 new prostate cancer susceptibility loci. Nature Genetics, 2018, 50, 928-936.	21.4	652
53	Fine-mapping of prostate cancer susceptibility loci in a large meta-analysis identifies candidate causal variants. Nature Communications, 2018, 9, 2256.	12.8	88
54	p73 Gene Promoter Methylation Patterns in Prostate Cancer Cell Lines. FASEB Journal, 2018, 32, 787.24.	0.5	0

#	Article	IF	CITATIONS
55	Polyphenon E Treatment Alters Gene Expression in Prostate Cancer Cells. FASEB Journal, 2018, 32, 804.61.	0.5	0
56	SNP interaction pattern identifier (SIPI): an intensive search for SNP–SNP interaction patterns. Bioinformatics, 2017, 33, 822-833.	4.1	11
57	miRNAs associated with prostate cancer risk and progression. BMC Urology, 2017, 17, 18.	1.4	79
58	Neural outcome processing of peer-influenced risk-taking behavior in late adolescence: Preliminary evidence for gene × environment interactions Experimental and Clinical Psychopharmacology, 2017, 25, 31-40.	1.8	10
59	Height, selected genetic markers and prostate cancer risk: results from the PRACTICAL consortium. British Journal of Cancer, 2017, 117, 734-743.	6.4	7
60	Mindfulness-Based Stress Reduction in Post-treatment Breast Cancer Patients: Immediate and Sustained Effects Across Multiple Symptom Clusters. Journal of Pain and Symptom Management, 2017, 53, 85-95.	1.2	120
61	Alcohol consumption and prostate cancer incidence and progression: A Mendelian randomisation study. International Journal of Cancer, 2017, 140, 75-85.	5.1	28
62	Two Novel Susceptibility Loci for Prostate Cancer in Men of African Ancestry. Journal of the National Cancer Institute, 2017, 109, .	6.3	57
63	RHCG and TCAF1 promoter hypermethylation predicts biochemical recurrence in prostate cancer patients treated by radical prostatectomy. Oncotarget, 2017, 8, 5774-5788.	1.8	22
64	Randomized, placebo-controlled trial evaluating the safety of one-year administration of green tea catechins. Oncotarget, 2016, 7, 70794-70802.	1.8	41
65	<i>PALB2</i> , <i>CHEK2</i> and <i>ATM</i> rare variants and cancer risk: data from COGS. Journal of Medical Genetics, 2016, 53, 800-811.	3.2	174
66	miR-1207-3p Is a Novel Prognostic Biomarker of Prostate Cancer. Translational Oncology, 2016, 9, 236-241.	3.7	16
67	Genome-Wide Meta-Analyses of Breast, Ovarian, and Prostate Cancer Association Studies Identify Multiple New Susceptibility Loci Shared by at Least Two Cancer Types. Cancer Discovery, 2016, 6, 1052-1067.	9.4	157
68	Atlas of prostate cancer heritability in European and African-American men pinpoints tissue-specific regulation. Nature Communications, 2016, 7, 10979.	12.8	50
69	Chemoprevention in African American Men with Prostate Cancer. Cancer Control, 2016, 23, 415-423.	1.8	5
70	Examination of Broad Symptom Improvement Resulting From Mindfulness-Based Stress Reduction in Breast Cancer Survivors: A Randomized Controlled Trial. Journal of Clinical Oncology, 2016, 34, 2827-2834.	1.6	165
71	Coexpression and expression quantitative trait loci analyses of the angiogenesis gene-gene interaction network in prostate cancer. Translational Cancer Research, 2016, 5, S951-S963.	1.0	11
72	Racial Differences in the Diagnosis and Treatment of Prostate Cancer. International Neurourology Journal, 2016, 20, S112-119.	1.2	63

#	Article	IF	CITATIONS
73	Prediction of individual genetic risk to prostate cancer using a polygenic score. Prostate, 2015, 75, 1467-1474.	2.3	54
74	Course and Predictors of Cognitive Function in Patients With Prostate Cancer Receiving Androgen-Deprivation Therapy: A Controlled Comparison. Journal of Clinical Oncology, 2015, 33, 2021-2027.	1.6	163
75	Epigenetic modulation of Chlorella (Chlorella vulgaris) on exposure to polycyclic aromatic hydrocarbons. Environmental Toxicology and Pharmacology, 2015, 40, 758-763.	4.0	2
76	Detoxification of chlorella supplement on heterocyclic amines in Korean young adults. Environmental Toxicology and Pharmacology, 2015, 39, 441-446.	4.0	10
77	A Large-Scale Analysis of Genetic Variants within Putative miRNA Binding Sites in Prostate Cancer. Cancer Discovery, 2015, 5, 368-379.	9.4	56
78	Generalizability of established prostate cancer risk variants in men of <scp>A</scp> frican ancestry. International Journal of Cancer, 2015, 136, 1210-1217.	5.1	62
79	Silencing of miR-137 by aberrant promoter hypermethylation in surgically resected lung cancer. Lung Cancer, 2015, 89, 99-103.	2.0	11
80	Risk Analysis of Prostate Cancer in PRACTICAL, a Multinational Consortium, Using 25 Known Prostate Cancer Susceptibility Loci. Cancer Epidemiology Biomarkers and Prevention, 2015, 24, 1121-1129.	2.5	56
81	Moderating Effects of Genetic Polymorphisms on Improvements in Cognitive Impairment in Breast Cancer Survivors Participating in a 6-Week Mindfulness-Based Stress Reduction Program. Biological Research for Nursing, 2015, 17, 393-404.	1.9	19
82	Multiple novel prostate cancer susceptibility signals identified by fine-mapping of known risk loci among Europeans. Human Molecular Genetics, 2015, 24, 5589-5602.	2.9	67
83	Genome-Wide Association Study of Prostate Cancer–Specific Survival. Cancer Epidemiology Biomarkers and Prevention, 2015, 24, 1796-1800.	2.5	27
84	Course and Moderators of Hot Flash Interference during Androgen Deprivation Therapy for Prostate Cancer: A Matched Comparison. Journal of Urology, 2015, 194, 690-695.	0.4	17
85	The effects of mindfulness-based stress reduction on objective and subjective sleep parameters in women with breast cancer: a randomized controlled trial. Psycho-Oncology, 2015, 24, 424-432.	2.3	85
86	Tobacco smoking-response genes in blood and buccal cells. Toxicology Letters, 2015, 232, 429-437.	0.8	17
87	Promoter Hypermethylation as a Biomarker in Prostate Adenocarcinoma. Methods in Molecular Biology, 2015, 1238, 607-625.	0.9	12
88	Role of <i>p73 </i> Dinucleotide Polymorphism in Prostate Cancer and p73 Protein Isoform Balance. Prostate Cancer, 2014, 2014, 1-9.	0.6	6
89	<i>CHEK2</i> ^{â^—} 1100delC Mutation and Risk of Prostate Cancer. Prostate Cancer, 2014, 2014, 1-9.	0.6	51
90	Safety and Chemopreventive Effect of Polyphenon E in Preventing Early and Metastatic Progression of Prostate Cancer in TRAMP Mice. Cancer Prevention Research, 2014, 7, 435-444.	1.5	23

#	Article	IF	Citations
91	Global Transcriptome Analysis of Formalin-Fixed Prostate Cancer Specimens Identifies Biomarkers of Disease Recurrence. Cancer Research, 2014, 74, 3228-3237.	0.9	111
92	A meta-analysis of 87,040 individuals identifies 23 new susceptibility loci for prostate cancer. Nature Genetics, 2014, 46, 1103-1109.	21.4	408
93	Gene silencing of SLC5A8 identified by genome-wide methylation profiling in lung cancer. Lung Cancer, 2013, 79, 198-204.	2.0	26
94	Identification of 23 new prostate cancer susceptibility loci using the iCOGS custom genotyping array. Nature Genetics, 2013, 45, 385-391.	21.4	492
95	A meta-analysis of genome-wide association studies to identify prostate cancer susceptibility loci associated with aggressive and non-aggressive disease. Human Molecular Genetics, 2013, 22, 408-415.	2.9	118
96	Variation in <i>HNF1B</i> and Obesity May Influence Prostate Cancer Risk in African American Men: A Pilot Study. Prostate Cancer, 2013, 2013, 1-7.	0.6	14
97	Gene Variants in Angiogenesis and Lymphangiogenesis and Cutaneous Melanoma Progression. Cancer Epidemiology Biomarkers and Prevention, 2013, 22, 827-834.	2.5	17
98	Global Patterns of Prostate Cancer Incidence, Aggressiveness, and Mortality in Men of African Descent. Prostate Cancer, 2013, 2013, 1-12.	0.6	180
99	SNP-SNP Interaction Network in Angiogenesis Genes Associated with Prostate Cancer Aggressiveness. PLoS ONE, 2013, 8, e59688.	2.5	40
100	miR-21, miR-221 and miR-222 expression and prostate cancer recurrence among obese and non-obese cases. Asian Journal of Andrology, 2013, 15, 226-230.	1.6	42
101	Gene variants in the angiogenesis pathway and prostate cancer. Carcinogenesis, 2012, 33, 1259-1269.	2.8	35
102	SLC5A8 Nuclear Translocation and Loss of Expression are Associated With Poor Outcome in Pancreatic Ductal Adenocarcinoma. Pancreas, 2012, 41, 904-909.	1.1	12
103	Genetic predictors of fatigue in prostate cancer patients treated with androgen deprivation therapy: Preliminary findings. Brain, Behavior, and Immunity, 2012, 26, 1030-1036.	4.1	36
104	DNA Methylation in Promoter Region as Biomarkers in Prostate Cancer. Methods in Molecular Biology, 2012, 863, 67-109.	0.9	58
105	Protein Expressions and Genetic Variations of SLC5A8 in Prostate Cancer Risk and Aggressiveness. Urology, 2011, 78, 971.e1-971.e9.	1.0	6
106	Multi-institutional prostate cancer study of genetic susceptibility in populations of African descent. Carcinogenesis, 2011, 32, 1361-1365.	2.8	31
107	Validation of Genome-Wide Prostate Cancer Associations in Men of African Descent. Cancer Epidemiology Biomarkers and Prevention, 2011, 20, 23-32.	2.5	88
108	SLC5A8 Gene, A Transporter of Butyrate: A Gut Flora Metabolite, Is Frequently Methylated in African American Colon Adenomas. PLoS ONE, 2011, 6, e20216.	2.5	27

#	ARTICLE	IF	CITATIONS
109	Promoter Hypermethylation in Prostate Cancer. Cancer Control, 2010, 17, 245-255.	1.8	56
110	Identification of seven new prostate cancer susceptibility loci through a genome-wide association study. Nature Genetics, 2009, 41, 1116-1121.	21.4	389
111	Single Nucleotide Polymorphisms in DNA Repair Genes and Prostate Cancer Risk. Methods in Molecular Biology, 2009, 471, 361-385.	0.9	25
112	Silencing of the Candidate Tumor Suppressor Gene Solute Carrier Family 5 Member 8 (SLC5A8) in Human Pancreatic Cancer. Pancreas, 2008, 36, e32-e39.	1.1	55
113	Association Between Polymorphisms in HSD3B1 and UGT2B17 and Prostate Cancer Risk. Urology, 2007, 70, 374-379.	1.0	43
114	Candidate tumor suppressor gene SLC5A8 is frequently down-regulated by promoter hypermethylation in prostate tumor. Cancer Detection and Prevention, 2007, 31, 359-365.	2.1	40
115	Association Between Polymorphisms in the DNA Repair Genes X <i>RCC1</i> and <i>APE1</i> , and the Risk of Prostate Cancer in White and Black Americans. Journal of Urology, 2006, 175, 108-112.	0.4	65
116	Deletion Polymorphism of UDP-Glucuronosyltransferase 2B17 and Risk of Prostate Cancer in African American and Caucasian Men. Cancer Epidemiology Biomarkers and Prevention, 2006, 15, 1473-1478.	2.5	96
117	CpG island hypermethylation profiling of lung cancer using restriction landmark genomic scanning (RLGS) analysis. Cancer Biomarkers, 2005, 1, 193-200.	1.7	23
118	ASP85TYR POLYMORPHISM IN THE UDP-GLUCURONOSYLTRANSFERASE (UGT) 2B15 GENE AND THE RISK OF PROSTATE CANCER. Journal of Urology, 2004, 171, 2484-2488.	0.4	67
119	The human 8-oxoguanine DNA N-glycosylase 1 (hOGG1) DNA repair enzyme and its association with lung cancer risk. Pharmacogenetics and Genomics, 2004, 14, 103-109.	5.7	102
120	Therapeutic applications of three-dimensional organoid models in lung cancer. Organoid, 0, 1, e6.	0.0	0